In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abuse-Deterrent Formulations of Opioid Analgesics Face Uphill Battle

Development, Regulatory and Patient Access Challenges Persist

Executive Summary

Commitment by biopharma to the development of new abuse-deterrent formulations of opioid pain medications is hampered by unresolved issues of development complexity; cost and willingness of payers to reimburse; and regulatory requirements for extensive, industry-financed postmarketing studies. Less addictive alternatives to existing opioid drugs that effectively address the overdose challenge where it’s particularly lethal – through injecting and inhaling rather than oral formulation abuse – are unlikely to enter widespread use anytime soon.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts